SCHEMBL18586035

SCHEMBL18586035

Nc1cc(Cc2cccc(C(=O)O)c2)c(/N=N/c2ccc(Cl)cc2)c(N)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.45
▸ POLB P06746 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ MRGPRX4 Q96LA9 3/20 0.43
▸ CCNE2 O96020 1/20 0.42
▸ CCNE1 P24864 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ MPO P05164 4/20 0.42
▸ DHFR P00374 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ NR4A2 P43354 2/20 0.40
▸ RECQL P46063 1/20 0.40
▸ FOLH1 Q04609 1/20 0.39
▸ CCR2 P41597 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ AR P10275 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18586036 1.00 MAPT (0.45) MAPTPOLBTDP1KMT2AATM
SCHEMBL20515403 0.88 MPO (0.54) MAPTKMT2AMRGPRX4MPODHFR
SCHEMBL18620547 0.88 MPO (0.54) MAPTKMT2AMRGPRX4MPODHFR
SCHEMBL20515399 0.87 MPO (0.57) MAPTPOLBKMT2AMPONPC1
SCHEMBL18618777 0.87 MPO (0.57) MAPTPOLBKMT2AMPONPC1
SCHEMBL20672109 0.86 MAPT (0.44) MAPTTDP1KMT2AMPONPC1
SCHEMBL20515407 0.86 MPO (0.57) MAPTKMT2AMPONPC1RAB9A
SCHEMBL18620244 0.86 MPO (0.57) MAPTKMT2AMPONPC1RAB9A
SCHEMBL20515396 0.85 MPO (0.47) MAPTTDP1KMT2AMPODHFR
SCHEMBL18618821 0.85 MPO (0.47) MAPTTDP1KMT2AMPODHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180282320-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2018-10-04 — — US disclosed
WO-2017040451-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MYERS SQUIBB COMPANY (US) 2017-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180282320-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 MAPT 4399/4885POLB 1095/4885TDP1 790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback